Hello and welcome back to Sounds of Science for our special 2022 year in review.

My name is Dante and I am Yukopes Communications and Business Development Manager.

If you're interested in seeing up to date on all of the latest news and initiatives

within the world of European Life Sciences, then kindly hit the

subscribe button on your phone or device. Throughout 2022, there have been successes, challenges,

delays and change within the European pharmaceutical industry. We expect much more to come

in the new year. On the final episode of the year, we will unravel the past 12 months in European pharma and biotech legislation looking at everything from rare diseases to ATMPs and EUHTA to digital health.

Sharing key highlights and what to expect in 2020.

A quick introduction to our guests, who if you've listened to our podcast before, you should know very well.

Victor Martens, our government affairs manager.

I don't that.

Matthias Olsen, our public affairs and policy manager.

Hi, and Merry Christmas, everyone.

And Leander Vranckin, our digital health policy officer.

Hello, everyone.

All right, guys, if it's fine with you, I think we could just jump right in.

Victor, the revision of the OMP regulation will happen early next year in Q1.

As a buildup in 2022, what are some of the key updates that have happened and how has

you cope been present in the space? Thanks, Dante. No one need to think after a long, long

buildup, we're hoping to see what the commission has been cooking up for the OMP regulation next year.

It's been a few years in the making.

And, yeah, we hope it comes out a few one,

...